Onset: Slow. The cypionate ester takes 1-2 weeks to reach steady-state plasma levels. Anabolic effect is slow and quality-oriented, not dramatic.

Week 1-2: Severe PIP is the dominant subjective signal. Within 24-72 hours of injection: deep, throbbing, "knotted" pain at injection site that often peaks days 2-4 and persists 3-7 days. Sleep on the injected side disrupted. Walking / squatting / running affected. Some users experience PIP severe enough to make them limp visibly. Anabolic effect not yet detectable.

Week 2-4: PIP often persists but may decrease modestly as users adjust technique (split doses across 3 small weekly injections instead of 1 big one, rotate IM sites aggressively, dilute high-mg vials with sterile carrier oil before drawing, heat vial to ~37°C before drawing). Subtle subjective signals begin: slightly fuller / drier muscle look, modest strength uptick, no water retention. Libido often modestly elevated (DHT-class CNS effect).

Week 4-8: Peak effect window. Slow, lean accrual; modest strength gain; dry / vascular appearance at lower body fat; minimal cosmetic puffiness. Mood typically neutral to mildly elevated. HDL begins crashing on bloodwork (DHT-class lipid impact). Hematocrit climbs (parent boldenone pathway is strongly erythropoietic; DHB shares this — community signal). BP may rise.

Week 8-12: Full DHB effect. Visible lean accrual ~5-15 lb in responsive users (heavily training- and diet- and base-dose-dependent). Lipid panel typically shows significant HDL drop. HPG axis suppressed. Liver enzymes may bump modestly — Friedel 2006 documented liver weight elevation in the rat assay; magnitude in humans uncertain. Hair-loss-predisposed users may notice accelerated shedding.

Off-cycle / PCT: HPG recovery 8-12 weeks with PCT after a 12-week cypionate cycle (long ester clears slowly). Lipid recovery 8-16 weeks. Hair loss may be permanent. Persistent post-cycle hypogonadism documented in young AAS users (Rasmussen 2016) — the SKIP-AT-20 mechanism applies fully.

Honest variability: Substantial. AR sensitivity polymorphism (CAG repeat length) drives 2-3× variance in response across the AAS class. PIP severity also has notable inter-individual variance — some users describe it as "manageable" while others describe it as "the worst I've ever felt from any compound." Carrier oil composition, concentration, and injection technique account for much of the variance.

• Tolerance buildup: AR receptor downregulation modest at AAS-class doses; primary anabolic plateau is at 6-8 weeks for DHB at 400 mg/week. Diminishing returns past week 8-10. Hepatic burden cumulative across cycles even with hepatoprotective stacks.
• Recommended cycle: Don't. If used despite recommendation, 8-12 weeks at 200-400 mg/week with mandatory test base, regular bloodwork, and aggressive PIP-mitigation protocol. Maximum 12 weeks; longer cycles produce diminishing returns + accelerating side effects.
• Reset protocol (PCT): Standard cascade — clomiphene 50/50/25/25 mg over 4 weeks OR enclomiphene 12.5-25 mg/day for 4-6 weeks ± hCG 250-500 IU 2x/week during cycle. Start PCT 2-3 weeks after final cypionate injection. HPG recovery 8-12 weeks with PCT; longer without. Lipids 8-16 weeks. Renal trajectory should normalize within 4-12 weeks if no underlying damage; persistent elevation = nephrology referral.
• Re-cycling / "blast and cruise": Strongly discouraged at this archetype. Cumulative cardiovascular and renal burden compounds across cycles. The SKIP-AT-20 logic does not get easier with repeated exposure.

Synergistic with (legitimate medical context only)

• Testosterone (enanthate / cypionate, 200-400 mg/week) — Required test base. Non-negotiable for DHB monotherapy avoidance.
• HCG (250-500 IU 2x/week during cycle) — Maintains testicular volume / Leydig responsiveness; eases PCT.
• NAC, taurine, magnesium (kidney support during cycle) — Community recommendation given DHB's renal-strain signal. NAC additionally provides hepatic antioxidant support given the Friedel hepatomegaly signal.
• Cardio + low-dose aspirin / lipid-friendly diet — Class-level harm reduction for the lipid + CV impact.

Avoid stacking with

• Trenbolone — Both non-aromatizing potent androgens. Compounded HDL crash, magnified androgenic load, stacked CV + renal load. Among the worst recreational AAS combinations.
• Boldenone (Equipoise) — Mechanically redundant; DHB is the 5α-reduced version of boldenone. Same AR signaling, compounded androgenic load, no clear benefit over running either alone with a test base.
• Other DHT-class AAS (masteron, primobolan, winstrol, anavar) — Compounded androgenic load (hair, skin, prostate) and lipid impact (HDL crash). DHB is itself DHT-class — adding more DHT-class is redundant for muscle and additive for side effects.
• 17α-alkylated orals (anadrol, dianabol, anavar at high dose, winstrol) — Hepatotoxicity stacking on top of the Friedel hepatomegaly signal.
• Aromatase inhibitors (anastrozole, letrozole) — Mechanistically unnecessary for DHB itself; only consider if running aromatizing AAS at high doses.
• NSAIDs (chronic) — Renal + BP load stacking. Particularly relevant for combat athletes who often use chronic NSAIDs for joint / training pain — given community signal of DHB renal strain, this stack is poorly advised.
• Alcohol (heavy / regular) — Additive hepatic load.

Neutral / safe co-administration

• V4/V5 stack supplements — Mostly mechanistically neutral. NAC, magnesium, fish oil, vitamin D, creatine — no interaction. Caffeine — neutral but watch BP.
• Most CNS nootropics (modafinil, citicoline, alpha-GPC, racetams) — No direct mechanism interaction.
• TRT (already on testosterone for confirmed hypogonadism) — TRT base is the standard test pair; this is the legitimate medical context where DHB might theoretically be added (though even there, the case is weak vs. dose-titrated TRT alone).
• BPC-157, TB-500 — No interaction; peptide-class healing tools work independently of AAS axis.

• Warfarin / anticoagulants — AAS class generally potentiates warfarin (↑INR), risk of hemorrhage. Warfarin dose typically requires reduction during AAS therapy.
• Insulin / oral hypoglycemics — AAS may modestly improve insulin sensitivity; dose adjustment in diabetics.
• Antihypertensives — May require dose escalation due to AAS-driven BP elevation.
• CYP3A4 substrates — Minor interactions reported; clinically modest at standard doses.
• NSAIDs (chronic) — Renal load stacking (above).
• Other hepatotoxic drugs (statins, isoniazid, methotrexate, valproate, acetaminophen at chronic high dose) — Additive hepatic burden on top of Friedel hepatomegaly signal.

• AR CAG repeat polymorphism — Shorter CAG repeats = higher AR transcriptional activity; users with shorter repeats may be more responsive to anabolic effects (and side effects) at lower dose. CAG ~21 average; range 9-37. Relevant for response prediction once 23andMe data is available (~June 2026).
• 5α-reductase polymorphism — Largely irrelevant for DHB-specific clearance because DHB is already 5α-reduced. The molecule bypasses the 5α-reductase step entirely. This is mechanistically why finasteride / dutasteride can't rescue DHB-driven scalp shedding.
• CYP3A4/3A5 polymorphism — May modestly affect cypionate ester hydrolysis kinetics. Effect minor.
• HLA-B alleles relevant to DILI — Class-level concern for AAS-induced liver injury. No DHB-specific predictor identified.
• For this archetype: 23andMe results pending June 2026. Even with maximally favorable polymorphisms, the structural class effects (HPG suppression, lipid impact, renal load, PIP profile) are not pharmacogenomic — they're inherent to the molecule + dose + route. Genetics will not rescue this molecule for a 20-year-old combat athlete.

Bottom line on sourcing for this archetype: No legitimate pathway. Modern medical use does not exist. Recreational sourcing requires international pharmacy access or UGL with all attendant quality risks. For a 20-year-old MMA athlete + business owner, every viable sourcing path involves either (a) regulatory risk (DEA Schedule III possession), (b) tested-status risk (USADA / IBJJF / state athletic commission detection — career-ending), or (c) supply-chain quality risk (UGL contamination, mislabeling, dosing errors, severe PIP from poor formulation). There is no clean sourcing path for this archetype.

If used despite the SKIP recommendation:

Baseline (before starting)

• Liver: ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, albumin, PT/INR, hepatitis B/C serology
• Lipids: Total cholesterol, LDL-C, HDL-C, ApoB, triglycerides, Lp(a)
• Hormonal: Total + free testosterone, SHBG, estradiol (sensitive assay), LH, FSH, prolactin, DHT, PSA
• CBC: Hematocrit, hemoglobin, RBC, WBC, platelets
• Renal (critical): Creatinine, eGFR, cystatin C, BUN, urinalysis (protein, blood), urine microalbumin / albumin-creatinine ratio, baseline urine output sense
• Cardiac: Resting BP, ECG; echocardiogram baseline if extended use planned
• Hepatic imaging: Baseline abdominal ultrasound for liver/biliary architecture and kidney structure
• Glycemic: HbA1c, fasting glucose, fasting insulin

During use

• Week 4: full LFT, lipid panel, CBC, BP, renal panel — monitor cholestatic markers, HDL nadir, HCT trajectory, kidney trajectory
• Week 8: full LFT, lipid, hormonal panel, BP, renal panel — last data point if 8-week cycle
• Week 12: full panel — end of typical 12-week cycle
• HCT >54% = stop drug, consider therapeutic phlebotomy
• Creatinine rising >25% from baseline OR proteinuria on dipstick = stop drug, nephrology consult
• ALT/AST >3x ULN = stop drug
• BP >140/90 sustained = stop drug
• HDL drop >50% from baseline = stop drug

Post-cycle

• Week 4 post: LFT, lipid, hormonal panel, CBC, BP, renal panel
• Week 12 post: full panel — confirm normalization
• Week 24 post: hormonal panel — full HPG recovery timepoint; PCT decision
• Annual abdominal ultrasound for users with extended exposure (kidney + liver surveillance)